Oncology NEWS International Vol 14 No 1

Efforts Continue to Uncover Early Indicators of Clinical Effect

January 02, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

EGFR Variables Do Not Correlate With Response to Treatment With Gefitinib Plus Platinum-Based Chemotherapy

January 02, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Cetuximab Improves Efficacy of Cisplatin/Vinorelbine in EGFR-Positive NSCLC Patients

January 02, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Avastin/FOLFOX4 Improves Overall Survival in Pts With Advanced Colon Ca

January 01, 2005

BETHESDA, Maryland-Data from the randomized, phase III E3200 trial show that patients with advanced colorectal cancer who were treated with bevacizumab (Avastin) in combination with the oxaliplatin (Eloxatin)-based regimen known as FOLFOX4 had a significant survival advantage, compared with patients treated with FOLFOX4 alone. The National Cancer Institute (NCI) released the results from an interim analysis at the recommendation of the trial’s data monitoring committee (DMC), after the trial monitors determined that the study had met its primary endpoint of improved overall survival.

Study Supports Need for RT Post-Lumpectomy in Most Pts

January 01, 2005

ATLANTA-A randomized trial finds that most women aged 50 or older who underwent breast-conserving surgery for early-stage breast cancer need radiation therapy (RT) in addition to tamoxifen to minimize the risk of a breast relapse. However, the data also suggest that selected women aged 60 or older may be able to safely skip radiation therapy. Lead author Anthony W. Fyles, MD, a radiation oncologist at the Princess Margaret Hospital, Toronto, Canada, presented findings of the trial at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (abstract 2). (For a full report, see N Engl J Med 351:963-970, 2004).

BMS-354825 Overcomes Imatinib Resistance in CML

January 01, 2005

SAN DIEGO, California-An investigational drug, BMS-354825, overcame resistance to imatinib (Gleevec) in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) patients in two small but dramatic phase I trials presented at the 46th Annual Meeting of the American Society of Hematology (ASH). After up to 9 months of treatment with BMS-354825, 31 of 36 chronic-phase patients (86%) had a complete hematological response, Charles L. Sawyers, MD, a Howard Hughes Medical Institute researcher at UCLA, reported (abstract 1). Among 29 patients who reached 3 months on treatment and could be evaluated for cytogenetic response, 13 responses were observed overall, including 8 major cytogenetic responses (28%), of which 5 were complete.

High pCR Rate With Neoadjuvant Chemo-RT in Rectal Ca

January 01, 2005

ATLANTA-Two neoadjuvant chemoradiation regimens-one using hyperfractionated radiation therapy and one using intensified chemotherapy-achieved pathologic complete responses (pCRs) in more than one-fourth of patients with advanced distal rectal cancer, according to a randomized phase II study. Mohammed Mohiuddin, MD, presented the findings at the 46th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (abstract 16).

Kepivance Approved for Oral Mucositis in Hematologic Ca

January 01, 2005

ROCKVILLE, Maryland-The Food and Drug Administration (FDA) has approved Amgen’s Kepivance (pal-ifermin) for use in decreasing the incidence and duration of severe oral mucositis in hematologic cancer patients undergoing high-dose chemotherapy, with or without radiation, followed by bone marrow transplantation. The drug’s labeling recommends its intravenous administration for 6 days, 3 days before and 3 days after myelotoxic therapy.

Gefitinib/Gemcitabine Better Tolerated Than Gefitinib/Vinorelbine by Elderly Patients With Advanced NSCLC

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Panels of Markers for Erlotinib and Gefitinib Sensitivity Found in NSCLC Cell Lines

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Promising Early Results With Single-Agent Erlotinib in Recurrent Glioblastoma Multiforme

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Dosing Issues Raised in Study of Gefitinib in Newly Diagnosed Grade 4 Glioblastoma Multiforme

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

NSCLC Patients Who Have Never Smoked Gain Significantly When Erlotinib Is Added to Chemotherapy

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Cetuximab Active as Monotherapy for Recurrent NSCLC

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Antitumor Activity Seen in Trial of Erlotinib for Glioblastoma Multiforme in First Relapse

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Erlotinib Controls NSCLC in More Than 60% of Elderly Patients With Advanced NSCLC in Phase II Trial

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Gefitinib Shows Single-Agent Activity in Patients With Bronchoalveolar Carcinoma

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Early Study Shows 35% Response to SU011248 in Patients With Metastatic Renal Cell Carcinoma

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

TALENT/TRIBUTE Studies Evaluate Erlotinib With Chemotherapy as First-Line Tx for Advanced NSCLC

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Bevacizumab/Erlotinib Moves on to Phase II Randomized Trial Among Patients With Advanced NSCLC

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Bevacizumab/Erlotinib Regimen Produces Notable Clinical Benefits in Metastatic Renal Carcinoma

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.

Tarceva Approved by the FDA as Single-Agent Treatment for Advanced NSCLC

January 01, 2005

This supplement to Oncology News International includes 17 reportson clinical trials of targeted therapies used alone, in combination with chemotherapy,or in combination with each other in the treatment of non–small-cell lung cancer (NSCLC),bronchoalveolar carcinoma, glioblastoma multiforme, and renal cell carcinoma.Included is a report on a novel targeted agent recently approved for treatment of NSCLC.